Tags
- 03
- 22000
- 3
- 4
- 40 Years
- 6
- A
- ACCE
- Acro
- Across
- Acute
- Administration
- Advance, Indiana
- Advances
- Adverse
- Adverse event
- Adverse Events
- Advisory
- Advisory board
- AFC Ajax
- After Eight
- Agent
- Agriculture in the United States
- An
- Analysis
- Annual general meeting
- Antibody
- Anxiety
- Approximately
- Arms
- Artificial
- Artificial ventilation
- Ascending
- Assignment
- Assistance
- Association
- Autoimmune
- Bangladesh
- Baseline
- Baseline characteristic
- Baseline characteristics
- Bed
- Benefit
- Biomarker
- Block
- Boards
- Burden
- C1Q complex
- C5
- Care
- Cause
- Causes
- Chain
- Chair
- Changing the Game
- Characteristic
- Characterized
- Classic
- Clinical
- Clinical endpoint
- Clinical trial
- Combined arms
- Comparability
- Complement
- Complement pathway
- Concomitant
- Conducting
- Confidence
- Council
- Damage
- Data
- Designation
- Developer
- Disclosed
- Disease
- Disease burden
- Disorder
- Dose
- Double
- Drug
- Duration
- Early signs
- Eculizumab
- Effect
- Effect size
- Efficacy
- Emergency
- Emergency department
- Employment
- Endpoint
- Endpoints
- Establishment
- Estimation
- Europe
- European
- Exchange
- Expect
- Expectation
- Fast Track
- FDA
- Fda-approved
- Food
- Food and Drug Administration
- Full Spectrum
- Funding of science
- G4
- Gain
- GBS
- Goal
- Grade
- Grade 1
- Grade 2
- Greater
- Guillain–Barré syndrome
- Health
- Hint
- Hospital
- Humanized antibody
- I.C.U.
- Immunoglobulin therapy
- Immunopathogenesis
- Immunotherapy
- Indication
- Indoor Living
- In Europe
- Inflammatory
- Infusion
- Inhibition
- Inhibitor
- Initiation
- Insignificance
- International
- Intervention
- Intravenous therapy
- Investigator
- Jennifer Haigh
- Kingdom
- Kroon
- Lead-in
- Levels
- Light
- Light chain
- Likelihood function
- Limited-access road
- London
- London United
- Long term
- Loss
- Lucy Prebble
- Lunn
- Manipulation
- M.D.
- MD–PhD
- Mean Time
- Mechanical
- Medical
- Medical News Schering
- Medical research
- Medical Research Council
- Medicine
- Medscape
- Men
- Mend
- Michael Lunn
- Mild Grade
- Moderate
- Modifications
- Monoclonal
- Monoclonal antibody
- Montreal
- Most
- MRC
- Much
- Muscle
- Muscle weakness
- Narrow
- National Hospital
- Nerve
- Nerve Damage
- Neurofilament
- Neuroimmunology
- Neurological disorder
- Neurology
- New
- New Normal
- No
- Normal
- Noted
- Not insignificant
- Observation
- Odd
- Odds
- Odds ratio
- Only
- Onset
- Orphan
- Orphan drug
- Over
- P
- Paralysis
- Participation
- Path
- Pathway
- Patient
- Peripheral
- Pharmaceutical drug
- Phase
- Phase 3
- Phases of clinical research
- PHD
- Phenotype
- Physician
- Placebo
- Plasma
- Plasmapheresis
- PNS
- Pointed
- Population
- Predominant chord
- Presenting
- Press release
- Prevalence
- Prevention
- Primary
- Professor
- Promising
- Protocol
- Psychological trauma
- Quotation
- Random
- Random assignment
- Randomness
- Rapid
- Reaching
- Reaction
- Realistic
- Real World
- Recombinant
- Recover
- Recovery
- Reduce
- Reducing
- Reduction
- Refer
- Representative
- Research
- Result
- Safe
- Safer
- Scale
- Score
- Secondary
- Secondary endpoints
- Serum
- Serum level
- Severity
- Signs
- Single
- Six Days
- Some
- Sooner
- Space
- Specific
- Spectrum
- Speed
- Speeding
- State of health
- Statistical significance
- Statistics
- Still
- Strength
- Studie
- Subgroup
- Subgroup analysis
- Substantial
- Sum Score
- Superior
- Supportive
- Sustain
- Syndrome
- Targeted
- Tengzhou
- Term
- Terms
- The best
- The european
- The first
- The Mend
- The national
- The Peripheral
- Therapeutic efficacy
- Therapy
- The time
- The Uncertain Path
- Transient
- Translation
- Translational medicine
- Trauma
- Trial
- Trials
- Uncertain
- Under Control
- Understood
- United Kingdom
- United State
- V
- Ventilation
- Walk
- Walking
- Weakness
- Western
- Who
- Window